Pfizer has caught investors’ eyes recently, outperforming its peers slightly but facing modest growth prospects ahead.

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

Penserra Capital Management significantly slashed its Pfizer holdings by 67%, selling nearly 15,800 shares, leaving a stake ...

Mr. Mahatme brings decades of experience in strategic finance, capital formation, and operational leadership to support company's transformation and growth in autoimmune disease CAMBRIDGE, Mass., July ...

US regulators approved Moderna Inc.’s COVID-19 vaccine for children, but for a narrower group than before, continuing Robert ...

Stock indexes closed higher on Wall Street, enough to nudge the S&P 500 and the Nasdaq composite to more records. The S&P 500 ...

The Dow Jones Industrial Average climbed on Thursday (July 10) as investors brushed aside concerns over new tariff ...

U.S. stock indexes are mixed as Wall Street sizes up a batch of corporate quarterly results. Delta Air Lines led a rally in airline stocks after releasing a solid outlook ...

With a market cap of $145.7 billion, Pfizer Inc. (PFE) is a global, research-driven biopharmaceutical company, specializing ...

The Nasdaq composite inched fractionally higher in Tuesday's session. The S&P 500 shed less than 0.1%. Small caps led the ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions ...